Home » PAIN THERAPEUTICS AND KING PHARMACEUTICALS GET SPECIAL PROTOCOL ASSESSMENT FOR REMOXY
PAIN THERAPEUTICS AND KING PHARMACEUTICALS GET SPECIAL PROTOCOL ASSESSMENT FOR REMOXY
Pain Therapeutics and King Pharmaceuticals have announced that Remoxy has successfully
completed a special protocol assessment with the FDA. As a result, the companies
are commencing a pivotal Phase III trial with Remoxy in 400 patients with severe
chronic pain.
Remoxy, an investigational drug, is an abuse-resistant version of long-acting
oxycodone, a strong opioid painkiller. Remoxy is intended to meet the needs
of physicians who appropriately prescribe oxycodone and who seek to minimize
risks of drug diversion, abuse or accidental patient misuse.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May